Effects of sodium citrate and acid citrate dextrose solutions on cell counts and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel

BMC Veterinary Research

Jorge U Carmona¹  María E Álvarez¹  Carlos E Giraldo¹ 

[1] Grupo de Investigación Terapia Regenerativa, Departamento de Salud Animal, Universidad de Caldas, Manizales, Colombia

关键词: Regenerative therapy;    Platelet derived growth factor isoform BB;    Transforming growth factor beta 1;    Platelet concentrate;    Horse;    Anticoagulant;   

Others  :  1140547
DOI  :  10.1186/s12917-015-0370-4

 received in 2014-10-21, accepted in 2015-02-24,  发布年份 2015

【 摘 要 】

Background

There is a lack information on the effects of the most commonly used anticoagulants for equine platelet rich plasmas (PRPs) elaboration on cell counts and growth factor release from platelet rich gels (PRGs). The aims of this study were 1) to compare the effects of the anticoagulants sodium citrate (SC), acid citrate dextrose solution A (ACD-A) and ACD-B on platelet (PLT), leukocyte (WBC) and on some parameters associated to platelet activation including mean platelet volume (MPV) and platelet distribution width (PDW) between whole blood, pure PRP (P-PRP) and platelet-poor plasma (PPP); 2) to compare transforming growth factor beta 1 (TGF-β₁) and platelet-derived growth factor isoform BB (PDGF-BB) concentrations in supernatants from pure PRG (P-PRG), platelet-poor gel (PPG), P-PRP lysate (positive control) and plasma (negative control); 3) to establish the possible correlations between all the studied cellular and molecular parameters.

Results

In all cases the three anticoagulants produced P-PRPs with significantly higher PLT counts compared with whole blood and PPP. The concentrations of WBCs were similar between P-PRP and whole blood, but significantly lower in PPP. The type of anticoagulant did not significantly affect the cell counts for each blood component. The anticoagulants also did not affect the MPV and PDW parameters. Independently of the anticoagulant used, all blood components presented significantly different concentrations of PDGF-BB and TGF-β₁. The highest growth factor (GF) concentrations were observed from P-PRP lysates, followed by PRG supernatants, PPP lysates, PPG supernatants and plasma. Significant correlations were observed between PLT and WBC counts (ρ = 0.80), PLT count and TGF-β₁ concentration (ρ = 0.85), PLT count and PDGF-BB concentration (ρ = 0.80) and PDGF-BB and TGF-β₁ concentrations (ρ = 0.75). The type of anticoagulant was not correlated with any of the variables evaluated.

Conclusions

The anticoagulants did not significantly influence cell counts or GF concentrations in equine PRP. However, ACD-B was apparently the worst anticoagulant evaluated. It is necessary to perform additional research to determine the effect of anticoagulants on the kinetics of GF elution from P-PRG.

【 授权许可】

   
2015 Giraldo et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Castelijns G, Crawford A, Schaffer J, Ortolano GA, Beauregard T, Smith RKW: Evaluation of a filter-prepared platelet concentrate for the treatment of suspensory branch injuries in horses. Vet Comp OrthopTraumatol 2011, 24(5):363-9.
• [2]Carmona JU, López C, Sandoval JA: Review of the currently available systems to obtain platelet related products to treat equine musculoskeletal injuries. Rec Pat Reg Med 2013, 3(2):148-59.
• [3]López C, Carmona JU: Platelet-rich plasma as an adjunctive therapy for the management of a severe chronic distal limb wound in a foal. J Equine Vet Sci 2014, 34(9):1128-33.
• [4]Iacopetti I, Perazzi A, Ferrari V, Busetto R: Application of platelet-rich gel to enhance wound healing in the horse: a case report. J Equine Vet Sci 2012, 32(3):123-8.
• [5]Bazzano M, Piccione G, Giannetto C, Tosto F, Di Pietro S, E. G : Platelet rich plasma intralesional injection as bedside therapy for tendinitis in athletic horse. Acta Sci Vet 2013, 41:1145.
• [6]Giraldo CE, López C, Álvarez ME, Samudio IJ, Prades M, Carmona JU: Effects of the breed, sex and age on cellular content and growth factor release from equine pure-platelet rich plasma and pure-platelet rich gel. BMC Vet Res 2013, 9:29. BioMed Central Full Text
• [7]Carmona J, López C, Giraldo C: Uso de concentrados autólogos de plaquetas como terapia regenerativa de enfermedades crónicas del aparato musculoesquelético equino. Arch Med Vet 2011, 43(1):1-10.
• [8]Dohan Ehrenfest DM, Bielecki T, Mishra A, Borzini P, Inchingolo F, Sammartino G, Rasmusson L, Evert PA: In search of a consensus terminology in the field of platelet concentrates for surgical use: platelet-rich plasma (PRP), platelet-rich fibrin (PRF), fibrin gel polymerization and leukocytes. Currt Pharm Biotechnol 2012, 13(7):1131-7.
• [9]McCarrel TM, Minas T, Fortier LA: Optimization of leukocyte concentration in platelet-rich plasma for the treatment of tendinopathy. J Bone Joint Surg Am 2012, 94(19):e143.141-e143.148.
• [10]Mazzucco L, Balbo V, Cattana E, Guaschino R, Borzini P: Not every PRP-gel is born equal Evaluation of growth factor availability for tissues through four PRP-gel preparations: Fibrinet®; RegenPRP-Kit®; Plateltex®; and one manual procedure. Vox Sang 2009, 97(2):110-8.
• [11]O'Shaughnessey K, Matuska A, Hoeppner J, Farr J, Klaassen M, Kaeding C, Lattermann C, King W, Woodell-May J: Autologous protein solution prepared from the blood of osteoarthritic patients contains an enhanced profile of anti-inflammatory cytokines and anabolic growth factors. J Orthop Res 2014, 32(10):1349-55.
• [12]Lei H, Gui L, Xiao R: The effect of anticoagulants on the quality and biological efficacy of platelet-rich plasma. Clin Biochem 2009, 42(13–14):1452-60.
• [13]Vendruscolo CP, Carvalho AM, Moraes LF, Maia L, Queiroz DL, Watanabe MJ, Yamada ALM, Alves ALG: Evaluating the effectiveness of different protocols for preparation of platelet rich plasma for use in equine medicine. Pesq Vet Bras 2012, 32(2):106-10.
• [14]Textor JA, Norris JW, Tablin F: Effects of preparation method, shear force, and exposure to collagen on release of growth factors from equine platelet-rich plasma. Am J Vet Res 2011, 72(2):271-8.
• [15]Textor JA, Tablin F: Activation of equine platelet-rich plasma: Comparison of methods and characterization of equine autologous thrombin. Vet Surg 2012, 41(7):784-94.
• [16]Argüelles D, Carmona JU, Pastor J, Iborra A, Viñals L, Martínez P, Bach E, Prades M: Evaluation of single and double centrifugation tube methods for concentrating equine platelets. Res Vet Sci 2006, 81(2):237-45.
• [17]Gornall AG, Bardawill CJ, David MM: Determination of serum proteins by means of the biuret reaction. J BiolChem 1949, 177(2):751-66.
• [18]Penha-goncalves MN, Onions DE, Nicolson L: Cloning and sequencing of equine transforming growth factor-beta 1 (TGF beta-1) cDNA. DNA Seq 1997, 7(6):375-8.
• [19]Donnelly BP, Nixon AJ, Haupt JL: Nucleotide structure of equine platelet-derived growth factor-A and –B and expression in horses with induced acute tendinitis. Am J Vet Res 2006, 67(7):1218-25.
• [20]Macey M, Azam U, McCarthy D, Webb L, Chapman ES, Okrongly D, Zelmanovic D, Newland A: Evaluation of the Anticoagulants EDTA and Citrate, Theophylline, Adenosine, and Dipyridamole (CTAD) for Assessing Platelet Activation on the ADVIA 120 Hematology System. Clin Chem 2002, 48(6):891-9.
• [21]Fontenot RL, Sink CA, Werre SR, Weinstein NM, Dahlgren LA: Simple tube centrifugation for processing platelet-rich plasma in the horse. Can Vet J 2012, 53(12):1266-72.
• [22]Silva RF, Carmona JU, Rezende CMF: Intra-articular injections of autologous platelet concentrates in dogs with surgical reparation of cranial cruciate ligament rupture. Vet Comp Orthop Traumatol 2013, 26(4):285-90.
• [23]O'Connell SM: Safety Issues Associated With Platelet-Rich Fibrin Method. Oral Surg, Oral Med, Oral Pathol, Oral Radiol Endodontol 2007, 103(5):587.
• [24]Álvarez ME, Giraldo CE, Carmona JU: Monitoring bacterial contamination in equine platelet concentrates obtained by the tube method in a clean laboratory environment under three different technical conditions. Equine Vet J 2010, 42(1):63-7.
• [25]Zimmermann R, Arnold D, Strasser E, Ringwald J, Schlegel A, Wiltfang J, Eckstein R: Sample preparation technique and white cell content influence the detectable levels of growth factors in platelet concentrates. Vox Sang 2003, 85(4):283-9.
• [26]Silva RF, Carmona JU, Rezende CMF: Comparison of the effect of calcium gluconate and batroxobin on the release of transforming growth factor beta 1 in canine platelet concentrates. BMC Vet Res 2012, 8:121. BioMed Central Full Text
• [27]López C, Giraldo CE, Carmona JU: Evaluation of a double centrifugation tube method for concentrating bovine platelets: Cellular study. Arch Med Vet 2012, 44(2):109-15.
• [28]Dragoo JL, Braun HJ, Durham JL, Ridley BA, Odegaard JI, Luong R, Arnoczky SP: Comparison of the acute inflammatory response of two commercial platelet-rich plasma systems in healthy rabbit tendons. Am J Sports Med 2012, 40(6):1274-81.